We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

White paper on lab-produced cannabinoids

22 Apr 2022 07:00

RNS Number : 9842I
Cellular Goods PLC
22 April 2022
 

Press release 

 

22 April 2022

 

Cellular Goods PLC

 

('Cellular Goods' or 'the Company')

 

Publication of white paper on sustainability of lab-produced cannabinoids

 

Cellular Goods (LSE: CBX), a UK-based wellness company that provides premium products formulated with lab-made cannabinoids, today announces the publication of a new white paper, 'Production of Cannabinoids Using Biotechnology and Synthetic Chemistry as a Path to Sustainability', which explores the improved sustainability and increased purity of lab-based production of cannabinoids when compared with traditional agricultural production.

 

Until recently, global demand for cannabinoids, primarily driven by sales of cannabidiol (CBD), has been satisfied by agricultural cultivation of the cannabis sativa plant from which these are extracted. However, this is a highly inefficient process. Cannabinoids make up just 2-5% of the plant by mass, which leads to approximately 90% of the plant ending up as botanical waste. Additionally, agricultural production is plagued by high land and water use, yield variability, potential microbial and chemical contamination and crop loss.

 

With the global market for CBD increasing by an annual compound growth rate of 21.3%, the market is expected to grow from US$4.9 billion in 2021 to US$47.22 billion by 2028, according to Vantage Market Research. Attempting to satisfy this increased demand with agricultural methods is likely to have a significant environmental cost and cause a production bottleneck, the white paper warns. (Source: Vantage Market Research, 2022, Cannabidiol Market Projected to Reach Valuation of USD 47.22 Billion by 2028).

 

Cellular Goods' white paper also reveals that biotechnology and synthetic chemistry allow cannabinoids to be produced at a commercial scale with increased purity, upwards of 95%, and significantly decreased environmental drawbacks compared with agricultural production. To produce 1,000kg of cannabigerol (CBG), a rare breakthrough cannabinoid, outdoor production requires 208% more time, and requires 40 acres of land, where lab-based production requires less than one acre. Furthermore, in outdoor CBD production, Carbon Dioxide (CO2) emissions are 44 times higher than by biosynthesis and requires 333 times more water. For biomass waste, biosynthesis produces 99.93% less waste than agricultural production.

 

Cellular Goods' products are exclusively formulated with lab-produced cannabinoids, and this white paper demonstrates how the Company remains committed to ethically and sustainably sourcing the components of its products.

 

The white paper is available to view here.

 

Anna Chokina, Chief Executive Officer, commented: "The publication of today's white paper illustrates our continued commitment to creating environmentally conscious, efficacy-led products. Cellular Goods exclusively uses lab-produced cannabinoids in its products, and this decision is fully vindicated by this white paper.

 

"Not only is the production process more sustainable, requiring less land, water and producing greatly decreased biomass waste and carbon emissions than agricultural production, but lab production gives the opportunity to increase production without suffering systemic and biological restraints. Use of lab production provides a greater ability to respond to any increases in demand in the cannabinoid space, as consumers become increasingly conscious of the effective skincare and wellness applications of cannabinoids."

 

Istok Nahtigal, Head of Process and Applied Sciences, commented: "Our research has further evidenced Cellular Goods' existing belief that lab-production methods for producing cannabinoids are the future. As consumers become increasingly environmentally conscious, it is important to prioritise ecological methods of production. Lab-production is a win-win for the Company, as it is not only more sustainable, but produces purer, higher quality products."

 

 

For further information please contact:

 

Cellular Goods

Anna Chokina

Chief Executive

Neil Thapar

Investor Relations

via Tancredi +44 207 887 7633

 

+44 787 645 5323

Tennyson Securities

Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427 

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Gabriela Amaya Garcia

Charlie Hobbs

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 791 503 5294

+44 789 755 7112

 

About Cellular Goods PLC:

Cellular Goods is a UK-based wellness company that provides premium products based on lab-made cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid-powered wellness products. The initial focus is on three product verticals: Function Better, Feel Better and Look Better. These three verticals encompass Cellular's premium CBG skincare and CBD ingestible and topical athletic recovery products, with the first products launched in December 2021 initially through the Company's website. The Company's shares are listed on the main market of the London Stock Exchange. www.cellular-goods.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAPPUWWCUPPPWG
Date   Source Headline
9th Mar 202111:05 amRNSSecond Price Monitoring Extn
9th Mar 202111:00 amRNSPrice Monitoring Extension
2nd Mar 20212:06 pmRNSSecond Price Monitoring Extn
2nd Mar 20212:00 pmRNSPrice Monitoring Extension
2nd Mar 20219:05 amRNSSecond Price Monitoring Extn
2nd Mar 20219:00 amRNSPrice Monitoring Extension
1st Mar 20214:41 pmRNSSecond Price Monitoring Extn
1st Mar 20214:36 pmRNSPrice Monitoring Extension
1st Mar 20219:05 amRNSSecond Price Monitoring Extn
1st Mar 20219:00 amRNSPrice Monitoring Extension
26th Feb 20212:05 pmRNSSecond Price Monitoring Extn
26th Feb 20212:00 pmRNSPrice Monitoring Extension
26th Feb 20219:05 amRNSSecond Price Monitoring Extn
26th Feb 20219:00 amRNSPrice Monitoring Extension
26th Feb 20217:00 amRNSFirst Day of Dealings
16th Mar 201210:04 amPRNPossible Cancellation of AIM Listing
12th Mar 201212:16 pmPRNAGM Statement and Directorate Changes
6th Feb 20127:00 amPRNFinal Results
3rd Oct 20117:00 amPRNPlacing and Issue of Equity
28th Sep 20113:00 pmRNSSuspension - Cubus Lux Plc
28th Sep 20113:00 pmPRNSuspension pending publication of annual accounts
14th Jul 20115:42 pmPRNPlacing and Issue of Equity
13th Jul 20117:00 amPRNPlacing and Issue of Equity - Corrective Announcement
12th Jul 20119:07 amPRNPlacing and Issue of Equity
3rd Jun 20117:00 amPRNChange of Broker
4th May 20118:43 amPRNPlacing and Issue of Equity
5th Apr 20117:00 amPRNIssue of equity and Trading update
15th Feb 20117:00 amPRNIssue of Equity
23rd Dec 20108:15 amPRNIssue of Equity
22nd Dec 20107:00 amPRNHalf-yearly Report
3rd Nov 201010:54 amPRNCorrection : Nominated Adviser - Change of Name
3rd Nov 20107:00 amPRNNominated Adviser and Broker - Change of Name
28th Oct 201011:10 amPRNResult of AGM
28th Oct 201010:00 amPRNAGM Statement
27th Sep 20104:15 pmRNSFinal Results
31st Aug 20107:00 amPRNIssue of Equity
14th Jul 20107:00 amPRNIssue of Equity
2nd Jul 20107:00 amRNSGrant of Options
7th May 20107:00 amRNSRe-pricing of Options
23rd Feb 20104:23 pmPRNDirector's Dealing
31st Dec 20097:00 amRNSExtension of Casino Licences and Issue of Equity
22nd Dec 20097:00 amPRNHalf-yearly Report
21st Dec 20099:16 amPRNChange of Adviser
3rd Nov 20091:04 pmPRNResult of AGM
9th Oct 200910:16 amPRNNotice of AGM
30th Sep 20097:00 amPRNFinal Results
30th Jun 20099:51 amPRNIssue of Equity
11th May 200912:42 pmPRNTrading Statement
29th Apr 20097:00 amPRNTender win - Valdanos, Montenegro
2nd Apr 200910:23 amPRNTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.